Biopharmaceutical company
Tax incentives for manufacturing RNA interference scientific advancements; expanding patient access to the Medicare home infusion benefit for drugs newly approved by the FDA after the establishment of the home infusion benefit;  allowing for access to Part B infused drugs in the home setting for the duration of the COVID-19 public health emergency
TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid
136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 12 - White House Office
SPLITOAK STRATEGIES LLC
300 New Jersey Avenue, NW, Suite 900, Washington, DC, 20001, US
AMY JENSEN (1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs) SARAH KUEHL EGGE (1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction) AMY JENSEN (1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs)
1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs